SWOT Analysis for Vor Biopharma Inc

High Normalized Momentum Score
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Stocks whose current price is 20% higher than week low, and more than previous close
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
High Momentum Scores (Technical Scores greater than 50)
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Overbought by Money Flow Index (MFI)
Companies with Low Debt
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Stock gained more than 20% in one month
Stock with Low PE (PE < = 10)
Biggest Price Gainers from Open
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter

Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Inefficient use of shareholder funds - ROE declining in the last 2 years
Inefficient use of assets to generate profits - ROA declining in the last 2 years
Low Piotroski Score : Companies with weak financials
Declining profits every quarter for the past 2 quarters